On May 12, 2022 Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, reported that new clinical data on its lead investigational high-precision cell therapy, Orca-T, will be shared in an oral presentation at the hybrid European Hematology Association (EHA) (Free EHA Whitepaper) Congress from June 9-17, 2022, in Vienna, Austria (Press release, Orca Bio, MAY 12, 2022, View Source [SID1234614424]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Session: Clinical Studies in Transplantation
Title: Orca-T, an Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies
Abstract Number: S237
Date and Time: Sunday, June 12, at 11:30–12:45 CEST / 5:30AM–6:45AM EDT
Location: Hall Stolz 1-2
The presentation will highlight results from the single-center Phase 2 and multi-center Phase 1b trials of Orca-T in patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndromes (MDS). Data included in the abstract will be updated at the time of presentation.
The oral session will take place in Vienna and will be livestreamed on the EHA (Free EHA Whitepaper) Congress platform.
About Orca-T
Orca-T is an investigational, high-precision allogeneic cell therapy derived from the stem and immune cells from either related or unrelated HLA-matched donors. Orca-T is intended to safely replace a patient’s compromised blood and immune system with that from a healthy donor. Orca-T is currently being evaluated in a Phase 3 clinical trial for the treatment of multiple hematologic malignancies and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.